Clinical Trial Update: Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing etrasimod to placebo in moderately to severely active ulcerative colitis has completed; results were posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Etrasimod (etrasimod)

Snippet

Sponsor: Arena Pharmaceuticals | Conditions: Ulcerative Colitis | Phase 3 | Status: COMPLETED | Results posted: 2022-12-20